(0.33%) 5 116.61 points
(0.33%) 38 365 points
(0.36%) 15 986 points
(-0.93%) $83.07
(5.56%) $2.03
(0.35%) $2 355.30
(0.46%) $27.66
(4.03%) $959.25
(-0.26%) $0.932
(-0.41%) $10.98
(-0.57%) $0.796
(1.69%) $93.43
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 13.49%
Live Chart Being Loaded With Signals
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States...
Stats | |
---|---|
本日の出来高 | 484 509 |
平均出来高 | 1.23M |
時価総額 | 606.65M |
EPS | $0 ( 2024-03-25 ) |
次の収益日 | ( $-0.600 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -4.89 |
ATR14 | $0.0250 (0.21%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-17 | Skorpios Trust | Sell | 3 600 000 | Common Stock |
2024-04-01 | Ticho Barry | Sell | 442 | Stock Option (Right to Buy) |
2024-04-01 | Ticho Barry | Buy | 442 | Common Stock |
2024-04-01 | Ticho Barry | Sell | 9 426 | Common Stock |
2024-04-01 | Nash Huw M. | Sell | 50 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
-65.61 |
Last 99 transactions |
Buy: 2 052 338 | Sell: 5 167 636 |
ボリューム 相関
Stoke Therapeutics Inc 相関
10 最も正の相関 | |
---|---|
RMRM | 0.897 |
KINS | 0.882 |
NXTC | 0.865 |
NRBO | 0.861 |
AGLE | 0.858 |
TLGT | 0.857 |
SVOK | 0.857 |
BRQS | 0.853 |
AVCT | 0.853 |
PAIC | 0.853 |
10 最も負の相関 | |
---|---|
NRIM | -0.926 |
AMRB | -0.896 |
UFPT | -0.888 |
NETE | -0.887 |
VCYT | -0.886 |
MMAC | -0.885 |
PSL | -0.882 |
MMSI | -0.88 |
PODD | -0.879 |
SFM | -0.878 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Stoke Therapeutics Inc 相関 - 通貨/商品
Stoke Therapeutics Inc 財務諸表
Annual | 2023 |
収益: | $8.78M |
総利益: | $4.05M (46.14 %) |
EPS: | $-2.38 |
FY | 2023 |
収益: | $8.78M |
総利益: | $4.05M (46.14 %) |
EPS: | $-2.38 |
FY | 2022 |
収益: | $12.41M |
総利益: | $8.87M (71.50 %) |
EPS: | $-2.39 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-2.33 |
Financial Reports:
No articles found.
Stoke Therapeutics Inc
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。